Office of Research
Clinical Trials

Leading the Future of Clinical Medicine
The College of Medicine is a hub for groundbreaking clinical research. With over 30 specialized research units, our teams are dedicated to translating laboratory discoveries into life-saving clinical applications. From neurology to oncology, we provide the infrastructure and expertise necessary to push the boundaries of modern medicine.

Browse our Research Units below to view current study listings.

Clinical Trials Search

Michael D. Privitera, MD

Epilepsy

Phase 2

BHV7000 for Focal Epilepsy Study

This is a randomized, placebo-controlled trial testing BHV-7000 in adults with focal onset epilepsy that has not been controlled by prior medicines. The study has two parts. In Part A participants are randomly assigned to 25 mg, 50 mg of BHV-7000, or placebo. After Part A, Part B will begin and will randomly assign participants to 75 mg BHV-7000 or placebo. Participants continue their usual anti-seizure medicines and record seizures during an 8-week observation phase, then receive 12 weeks of double-blind treatment. The main goal is to see whether BHV-7000 reduces 28-day average seizure frequency compared with baseline and to measure safety by tracking adverse events and lab abnormalities. Other goals include responder rates (50% and 75% seizure reduction), seizure freedom, early treatment effects (first week and first month), and patient global impression of change.

Learn More about BHV7000 for Focal Epilepsy Study

Michael D. Privitera, MD

Epilepsy

Testing a wearable device for seizures

This study tests a wearable device that tracks seizures, heart rhythm, breathing, and oxygen levels while people are already in the hospital for epilepsy monitoring. Participants wear the devices during their hospital stay. The information collected may help improve future seizure detection devices.

Michael D. Privitera, MD

Epilepsy

FORETELL: How Daily Patterns and Wearables May Help Forecast Seizures

The FORETELL Study wants to learn whether everyday patterns can help people know when a seizure might be more likely. Participants use a phone app to check in each day and answer simple questions about their sleep, stress, mood, and any seizures they had. They also wear a smartwatch that tracks things like heart rate, sleep quality, and activity. Some people will give small saliva samples so the research team can look at natural stress levels. By combining information from the app, the watch, and the saliva samples, the study hopes to find patterns that could give early clues about when a seizure might happen. The goal is to help people living with epilepsy better understand their own patterns and feel more prepared in their daily lives. No treatments are being tested, and participants continue their usual medical care throughout the study.

Michael D. Privitera, MD

Epilepsy

Phase 1

Cannabidiol for Focal Seizures Study

This is an open-label, single-group study testing a cannabidiol (CBD) oral solution as an extra medicine for people with focal-onset seizures aged 12 to 75. Participants will keep their current anti-seizure medicines (1 to 4 drugs) and add the CBD solution. The main goal is to see whether CBD lowers the number of focal seizures compared to each person's baseline over about 16 weeks. The study will also look at safety, how the body handles the drug (pharmacokinetics), and whether brain imaging (fMRI) or thinking tests predict who responds best. Some people in the study may be early in their treatment and others may have hard-to-treat seizures. The study does not include people with non-epileptic events, recent CBD or cannabis use, certain allergies, or unstable medical or mental-health issues.

Learn More about Cannabidiol for Focal Seizures Study